Markets

Early-stage biotech Mersana Therapeutics prices IPO at $15, within the range

Mersana Therapeutics, an early-stage biotech developing antibody drug conjugate therapies for cancers, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Mersana Therapeutics plans to list on the Nasdaq under the symbol MRSN. J.P. Morgan, Cowen & Company and Leerink Partners acted as lead managers on the deal.

The article Early-stage biotech Mersana Therapeutics prices IPO at $15, within the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRSN

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More